{"altmetric_id":1642411,"counts":{"readers":{"mendeley":15,"citeulike":0,"connotea":0},"facebook":{"unique_users_count":1,"unique_users":["206667566365336"],"posts_count":1},"policy":{"unique_users_count":1,"unique_users":["nice"],"posts_count":1},"total":{"posts_count":5},"twitter":{"unique_users_count":3,"unique_users":["mnewtonPharmD","scimegaresearch","AlanCoo51487198"],"posts_count":3}},"selected_quotes":["More evidence for the durability of responses to ipilimumab in #melanoma","4y survival rates for patients with met. melanoma who received ipilimumab in phase II clinical trials"],"citation":{"abstract":"This analysis was carried out to evaluate the long-term survival of patients with metastatic melanoma who received ipilimumab, a fully human monoclonal antibody that binds to cytotoxic T-lymphocyte antigen-4, in clinical trials.","abstract_source":"pubmed","altmetric_jid":"4f6fa4e83cf058f610002280","authors":["C. Lebb\u00e9","Wolchok JD","Weber JS","Maio M","Neyns B","Harmankaya K","Chin K","Cykowski L","de Pril V","Humphrey R","Lebb\u00e9 C","Wolchok, J. D.","Weber, J. S.","Maio, M.","Neyns, B.","Harmankaya, K.","Chin, K.","Cykowski, L.","de Pril, V.","Humphrey, R.","Lebb\u00e9, C.","J. D. Wolchok","J. S. Weber","M. Maio","B. Neyns","K. Harmankaya","K. Chin","L. Cykowski","V. de Pril","R. Humphrey"],"doi":"10.1093\/annonc\/mdt161","endpage":"2180","first_seen_on":"2013-07-23T14:07:16+00:00","funders":["nci"],"issns":["1569-8041","0923-7534"],"issue":"8","journal":"Annals of Oncology","last_mentioned_on":1506805255,"links":["http:\/\/annonc.oxfordjournals.org\/content\/24\/8\/2174.short?rss=1","http:\/\/annonc.oxfordjournals.org\/content\/early\/2013\/05\/09\/annonc.mdt161.long","http:\/\/dx.doi.org\/10.1093\/annonc\/mdt161","https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4081656\/#!po=41.2500"],"pdf_url":"http:\/\/annonc.oxfordjournals.org\/content\/24\/8\/2174.full.pdf","pmid":"23666915","pubdate":"2013-01-01T00:00:00+00:00","publisher":"Oxford University Press","publisher_subjects":[{"name":"Oncology And Carcinogenesis","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"startpage":"2174","subjects":["neoplasms"],"title":"Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials","type":"article","uri":"https:\/\/academic.oup.com\/annonc\/article-lookup\/doi\/10.1093\/annonc\/mdt161","volume":"24","mendeley_url":"http:\/\/www.mendeley.com\/research\/fouryear-survival-rates-patients-metastatic-melanoma-received-ipilimumab-phase-ii-clinical-trials-4"},"altmetric_score":{"score":5.25,"score_history":{"1y":0.25,"6m":0.25,"3m":0.25,"1m":0.25,"1w":0.25,"6d":0.25,"5d":0.25,"4d":0.25,"3d":0.25,"2d":0,"1d":0,"at":5.25},"context_for_score":{"all":{"total_number_of_other_articles":8462498,"mean":7.1083922572655,"rank":1596103,"this_scored_higher_than_pct":81,"this_scored_higher_than":6858592,"rank_type":"exact","sample_size":8462498,"percentile":81},"similar_age_3m":{"total_number_of_other_articles":128830,"mean":7.1319680040986,"rank":24017,"this_scored_higher_than_pct":81,"this_scored_higher_than":104671,"rank_type":"exact","sample_size":128830,"percentile":81},"this_journal":{"total_number_of_other_articles":3669,"mean":9.779846782988,"rank":1063,"this_scored_higher_than_pct":70,"this_scored_higher_than":2600,"rank_type":"exact","sample_size":3669,"percentile":70},"similar_age_this_journal_3m":{"total_number_of_other_articles":31,"mean":5.5333333333333,"rank":10,"this_scored_higher_than_pct":67,"this_scored_higher_than":21,"rank_type":"exact","sample_size":31,"percentile":67}}},"demographics":{"poster_types":{"member_of_the_public":3},"users":{"twitter":{"cohorts":{"Members of the public":3}},"mendeley":{"by_status":{"Researcher":5,"Student  > Ph. D. Student":3,"Student  > Master":3,"Student  > Bachelor":3,"Student  > Postgraduate":1},"by_discipline":{"Medicine and Dentistry":6,"Immunology and Microbiology":2,"Agricultural and Biological Sciences":5,"Biochemistry, Genetics and Molecular Biology":2}}},"geo":{"twitter":{"US":2,"CA":1}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/mnewtonPharmD\/statuses\/360398770833330176","license":"datasift","citation_ids":[1642411],"posted_on":"2013-07-25T13:58:57+00:00","author":{"name":"Michael D. Newton","url":"http:\/\/www.linkedin.com\/pub\/michael-newton\/14\/b0b\/1b3","image":"https:\/\/pbs.twimg.com\/profile_images\/604112957170008064\/TGQ_7Kyr_normal.jpg","description":"Loves tech, coffee, food. Hates #cancer. Reformed academic. Views are my own.","id_on_source":"mnewtonPharmD","tweeter_id":"1506133160","geo":{"lt":38.50038,"ln":-80.50009,"country":"US"},"followers":486},"tweet_id":"360398770833330176"},{"url":"http:\/\/twitter.com\/scimegaresearch\/statuses\/359675809218306048","license":"public","rt":["feedly"],"citation_ids":[1642411],"posted_on":"2013-07-23T14:06:10+00:00","author":{"name":"OncologyExperts","url":"http:\/\/www.scimega.com","image":"https:\/\/pbs.twimg.com\/profile_images\/780562642968670210\/B6y_WawT_normal.jpg","description":"#Scimega | #Oncology CRO mission = attract #cancer #clinicaltrials to #Canada | Strictly Canada Strictly Oncology | Tweets are not endorsements","id_on_source":"scimegaresearch","tweeter_id":"36664403","geo":{"lt":45.50884,"ln":-73.58781,"country":"CA"},"followers":1187},"tweet_id":"359675809218306048"},{"url":"http:\/\/twitter.com\/AlanCoo51487198\/statuses\/691595757632294912","license":"gnip","citation_ids":[1642411],"posted_on":"2016-01-25T12:17:32+00:00","author":{"name":"Alan Cooper","image":"https:\/\/pbs.twimg.com\/profile_images\/812956740211740672\/y-9CyUPB_normal.jpg","id_on_source":"AlanCoo51487198","tweeter_id":"3856798395","geo":{"lt":33.749,"ln":-84.38798,"country":"US"},"followers":12},"tweet_id":"691595757632294912"}],"policy":[{"title":"Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma: Evaluation report","url":"https:\/\/www.nice.org.uk\/guidance\/TA319\/documents\/evaluation-report2","license":"public","citation_ids":[2044763,173660,18317344,634898,6093848,15779880,4931051,582057,2410863,21734927,5374798,15779893,15779895,6094246,18318493,15631765,8204270,15779902,3236832,690897,3105133,10299500,1679803,15779914,4323582,807146,13237246,1642411,17320722,5374785,951217,178826,15779931,2552510,6078796,234489,521217,21734941,774894,1346859,613722,15779948,15779966,15779984,15780001],"posted_on":"2014-02-25T00:00:00+00:00","source":{"name":"National Institute for Health and Care Excellence","description":"The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.","geo":{"country":"GB"}},"page_url":"https:\/\/www.nice.org.uk\/guidance\/ta319\/evidence","collections":[],"author":{"image":"https:\/\/s3.amazonaws.com\/cache.altmetric.com\/policy\/thumbnails\/thumbnail-59940bd851e7024e35e35dd7f8acdb64b67f56f2fc1bc7bf3401d7a06527ffca.jpg"}}],"facebook":[{"title":"Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=488612721504151&id=206667566365336","license":"public","citation_ids":[1642411],"posted_on":"2017-09-30T21:00:55+00:00","summary":"Clinical trial showing efficacy of ipilimumab, the FDA approved anti CTLA4 antibody...the original checkpoint inhibitor \n\nhttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4081656\/#!po=41.2500","author":{"name":"Pan American Cancer Treatment Centers","url":"https:\/\/www.facebook.com\/206667566365336","facebook_wall_name":"Pan American Cancer Treatment Centers","image":"https:\/\/graph.facebook.com\/206667566365336\/picture","id_on_source":"206667566365336"}}]}}